The association of the marker of cardiovascular RISK – QTc interval with 64V/64I CCR2 gene polymorphism and metabolic syndrome components In the general male population of Novosibirsk

   Myocardial electric instability, apparently , has a multigenic and multifactorial basis. It is interesting to examine of the association of the QTc interval with CC chemokine receptor 2 gene polymorphism (CCR2) and metabolic syndrome components. Survey data from a representative sample 831 men aged 25–64 out of a general population of Novosibirsk («MONICA» WHO project) were used. For genetic research by randomly were selected 393 people. The components of the metabolic syndrome (obesity, hypertension, hypertriglyceridemia and hypo-alpha-lipoproteinemia) were determined according to the WHO criteria. To calculate the corrected QTc interval Bazett formula has been used. The analysis in the multivariate linear regression model showed that the QTc interval was independently associated with 64V/64I(rs1799864) CCR2 gene polymorphism (p = 0.04) and hypertension (p = 0.0003).

1. Shouten E., Dekker J., Meppelink P. et al. QT interval prolongation predict cardiovascular mortality in an apparently healthy population // Circulation. 1991. Vol. 84 (4). P. 1516–1523.

2. Никитин Ю. П. Прогностическое значение длительности и вариабельности интервалов QT и RR в общей популяции Новосибирска / Ю. П. Никитин [и др.] // Кардиология. – 2002. – № 2. – С. 76–83.

3. Дощицин В. Л. Удлинение интервала QT на ЭКГ: классификация, клиническое значение / В. Л. Дощицин, Е. С. сигал, В. В. Седов // Кардиология. – 1981. – Т. 21 (10). – С. 22–28.

4. Moss A. J. Prolonged QT interval syndromes // JAMA. 1986. Vol. 256. P. 2985–2987.

5. Воевода М. И. Ассоциация индексов желудочковой реполяризации с полиморфизмом генов β1-адренорецептора и α2B-адренорецептора / М. И. Воевода [и др.[ // Бюл. СО РАМН. – 2007. – № 123 (1). – С. 11–14.

6. Воевода М. И. Связь полиморфизма гена хемокинового рецептора CCR2 с инфарктом миокарда / М. И. Воевода [и др.] // ДАН. – 2002. – Т. 385, № 2. – С. 279–282.

7. Petrkova J., Cermakova Z., Drabek J., Lukl J., Petrek M. CC chemokine receptor (CCR)2 polymorphism in Czech patients with myocardial infarction // Immunol. Lett. 2003. Vol. 8, N 1. P. 53–55.

8. Bursill C. A., Channon K. M., Greaves D. R. The role of chemokines in atherosclerosis: recent evidence from experimental models and population genetics // Curr. Opinion Lipid. 2004. Vol. 159 (2). P. 145–149.

9. Apostolakis S., Papadakis E., Krambovitis E. et al. Chemokines in vascular pathology (Review) // Int. J. Molecular Med. 2006. Vol. 17. P. 691–701.

10. Nyquist P. A., Winkler C. A., McKenzie L. M., Yanek L. R., Becker L. C., Becker D. M. Single nucleotide polymorphisms in monocyte chemoattractant protein-1 and its receptor act synergistically to increase the risk of carotid atherosclerosis // Cerebrovasc. Dis. 2009. Vol. 28 (2). P. 124–130.

11. Эпидемиологические методы исследования сердечно-сосудистых заболеваний / Д. Роуз [и др.] – ВОЗ. Серия монографий. – Женева, 1984.

12. Профилактика ИБС: Методическое указание / ВКНЦ АМН СССР; Ин-т профилактической кардиологии. – М., 1983.

13. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Report of a WHO consultation. Geneva: World Health Organization, 1999.

14. Ahnve S. Correction of the QT interval for heart rate: review of different formulas and the use of Bazett’s formula in myocardial infarction // Am. Heart J. 1985. Vol. 109. P. 568–574.

15. Surawicz B., Knoebel S. Long QT: good, bad or indiferent? // J. Am. Coll. Cardiol. 1984. Vol. 4. P. 398–413.

16. Никитин Ю. П. Дисперсия интервала QT / Ю. П. Никитин, А. А. Кузнецов // Кардиология. – 1998. – T. 38, № 5. – С. 58–63.

17. Bazett H. S. An analysis of time relations of electrocardiograms // Heart. 1920. Vol. 7. P. 353–367.

18. Taran L. M., Szilagyi N. The duration of the electrical systole (QT) in acute rheumatic carditis in children // Am. Heart J. 1947. Vol. 33. P. 14–26.

19. Смит К. Пульс-электрофорез и методы работы с большими молекулами ДНК. Анализ генома / К. Смит, С. Калко, Ч. Кантор; под ред. К. Дейвис. – М.: Мир, 1990. – С. 58–94.

20. Воевода М. И. Способ определения аллелей гена хемокинового рецептора CCR2 по полиморфному сайту V64I / М. И. Воевода [и др.] // Патент РФ. – № 2180922. – 27. 03. 2002.

21. Strohmer B., Schernthaner C., Iglseder B., Paulweber B., Pichler M. Gender-specific effect of metabolic syndrome on rate adjusted QT interval in middle-aged participants of an atherosclerosis prevention program // Wien. Klin. Wochenschr. 2007. Vol. 119. P. 544–552.

22. Faramawi M. F., Wildman R. P., Gustat J., Rice J., Abdul Kareem M. Y. The association of the metabolic-syndrome with QTc interval in NHANES III // Eur. J. Epidemiol. 2008. Vol. 23. P. 459–465.

23. Li W., Bai Y., Sun K., Xue H., Wang Y., Song X., Fan X., Song H., Han Y., Hui R. Patients with metabolic syndrome have prolonged corrected QT interval (QTc) // Clin. Cardiol. 2009. Vol. 32. P. 93–99.

24. Grandinetti A., Chow D. C., Miyasaki M., Low P. Association of increased QTc interval with the cardiometabolic syndrome // J. Clin. Hypertens. 2010. Vol. 12. P. 315–320.

25. Grandinetti A., Seifried S., Mor J., Chang H. K., Theriault A. G. Prevalence and risk factors for prolonged QTc in a multiethnic cohort in rural Hawaii // Clin. Biochem. 2005. Vol. 38. P. 116–122.

26. Szabó Z., Harangi M., Lörincz I., Seres I., Katona E., Karányi Z., Paragh G. Effect of hyperlipidemia on QT dispersion in patients without ischemic heart disease // Can. J. Cardiol. 2005. Vol. 21. P. 847–850.

27. Castro S. H., Faria-Neto H. C., Gomes M. B. QTc interval and traditional risk factors to atherosclerotic disease in patients with type 1 diabetes // Arq. Bras. Endocrinol. Metabol. 2007. Vol. 51. P. 1153–1159.